Table 1 EGFR/MSI1 mRNA expression and clinicopathological features of ESCC patients
| Â | Total | EGFR/ MSI1 over expression | EGFR/ MSI1 under expression | EGFR/ MSI1 normal expression | EGFR over expression | MSI1 over expression | P- Value |
|---|---|---|---|---|---|---|---|
Patients | 48 | 7(14.6%) | 2(4.2%) | 14(29.2%) | 12(25%) | 12(25%) | Â |
Mean age (mean ± SD) | 61.85 ± 12.33 | 55.86 ± 5.65 | 42.50 ± 6.50 | 66.43 ± 2.30 | 63.17 ± 2.36 | 60.58 ± 4.29 |  |
Size (mean ± SD) | 4.23 ± 1.91 | 3.50 ± 0.58 | 3.75 ± 1.75 | 4.20 ± 0.36 | 4.29 ± 0.58 | 4.88 ± 0.73 |  |
Sex | 0.553 | ||||||
 Male | 28(58.3%) | 5(71.4%) | – | 8(57.1%) | 8(66.7%) | 7(58.3%) |  |
 Female | 20(41.7%) | 2(28.6%) | 2(100%) | 6(42.9%) | 4(33.3%) | 5(41.7%) |  |
Location | 0.226 | ||||||
 Lower | 21(43.8%) | 2(28.6%) | – | 8(57.1%) | 4(33.3%) | 6(50%) |  |
 Middle | 27(56.2%) | 5(71.4%) | 2(100%) | 6(42.9%) | 8(66.7%) | 6(50%) |  |
Grade | 0.020 | ||||||
 Poorly differentiated | 8(16.7%) | 2(28.6%) | 2(100%) | 1(7.1%) | 1(8.3%) | 1(8.3%) |  |
 Moderately differentiated | 31(64.6%) | 5(71.4%) | – | 11(78.6%) | 8(66.7%) | 7(58.3%) |  |
 Well differentiated | 9(18.8%) | – | – | 2(14.3%) | 3(25%) | 4(33.3%) |  |
Lymph node metastasis | 0.702 | ||||||
 Yes | 22(45.8%) | 2(28.6%) | 1(50%) | 8(57.1%) | 4(33.3%) | 6(50%) |  |
 No | 26(54.2%) | 5(71.4%) | 1(50%) | 6(42.9%) | 8(66.7%) | 6(50%) |  |
Stage | 0.763 | ||||||
 I/II | 29(60.4%) | 5(71.4%) | 1(50%) | 7(50%) | 9(75%) | 7(58.3%) |  |
 III/IV | 19(39.6%) | 2(28.6%) | 1(50%) | 7(50%) | 3(25%) | 5(41.7%) |  |
Depth of tumor invasion (T) | 0.292 | ||||||
 T1 | 1(2.1%) | 1(14.3%) | – | – | – | – |  |
 T2 | 7(14.6%) | – | – | 2(14.3%) | 4(33.3%) | 1(8.3%) |  |
 T3 | 40(83.3%) | 6(85.7%) | 2(100%) | 12(85.7%) | 8(66.7%) | 11(91.7%) |  |